Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?

References

• AbrahamIAlhossanALeeCS“Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic reviewAllergy201671559361026644231
   PubMed Web of Science ®Google Scholar
• MenzellaFLusuardiMMontanariGClinical usefulness of mepolizumab in severe eosinophilic asthmaTher Clin Risk Manag20161290791627354806
   PubMed Web of Science ®Google Scholar
• TrivediAPavordIDCastroMBronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthmaLancet Respir Med20164758559227230825
   PubMed Web of Science ®Google Scholar
• WenzelSSevere asthma: from characteristics to phenotypes to endotypesClin Exp Allergy201242565065822251060
   PubMed Web of Science ®Google Scholar
• ChungKFAsthma phenotyping: a necessity for improved therapeutic precision and new targeted therapiesJ Intern Med2016279219220426076339
   PubMed Web of Science ®Google Scholar
• LotvallJAkdisCABacharierLBAsthma endotypes: a new approach to classication of disease entities within the asthma syndromeJ Allergy Clin Immunol2011127235536021281866
   PubMed Web of Science ®Google Scholar
• MooreWCMeyersDAWenzelSEIdentification of asthma phenotypes using cluster analysis in the severe asthma research programAm J Respir Crit Care Med2010181431532319892860
   PubMed Web of Science ®Google Scholar
• SimpsonATanVYWinnJSvensenMBeyond atopy: multiple patterns of sensitization in relation to asthma in a birth cohort studyAm J Respir Crit Care Med2010181111200120620167852
   PubMed Web of Science ®Google Scholar
• O’NeilSELundbäckBLötvallJProteomics in asthma and COPD phenotypes and endotypes for biomarker discovery and improved understanding of disease entitiesJ Proteomics201175119220122037230
   PubMed Web of Science ®Google Scholar
• SamitasKDelimpouraVZervasEAnti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectivesEur Respir Rev20152413859460126621973
   PubMed Web of Science ®Google Scholar
• HumbertMBusseWHananiaNAOmalizumab in asthma: an update on recent developmentsJ Allergy Clin Immunol Pract20142552553625213045
   PubMed Web of Science ®Google Scholar
• RodrigoGJNeffenHCastro-RodriguezJAEfficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic reviewChest20111391283520688929
   PubMed Web of Science ®Google Scholar
• LowePJTannenbaumSGautierARelationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthmaBr J Clin Pharmacol2009681617619660004
   PubMed Web of Science ®Google Scholar
• MenzellaFPiroRFacciolongoNLong-term benefits of omalizumab in a patient with severe non-allergic asthmaAllergy Asthma Clin Immunol201171921609447
   PubMed Web of Science ®Google Scholar
• ForesterJPCalabriaCWLocal production of IgE in the respiratory mucosa and the concept of entopy: does allergy exist in nonallergic rhinitis?Ann Allergy Asthma Immunol2010105424925520934624
   PubMed Web of Science ®Google Scholar
• BusseWWMorganWJGergenPJRandomized trial of omalizumab (anti-IgE) for asthma in inner-city childrenN Engl J Med201136411005101521410369
   PubMed Web of Science ®Google Scholar
• TeachSJGillMATogiasAPreseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbationsJ Allergy Clin Immunol201513661476148526518090
   PubMed Web of Science ®Google Scholar
• Giménez-ArnauAMToubiEMarslandAMMaurerMClinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticariaJ Eur Acad Dermatol Venereol201630Suppl 52532
   Web of Science ®Google Scholar
• BachertCGevaertPHellingsPBiotherapeutics in chronic rhinosinusitis with and without nasal polypsJ Allergy Clin Immunol Pract2017 pii:S2213-2198(17)30321-5. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• HananiaNAWenzelSRosénKExploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA studyAm J Respir Crit Care Med2013187880481123471469
   PubMed Web of Science ®Google Scholar
• LedfordDBusseWTrzaskomaBA randomized multicenter study evaluating Xolair persistence of response after long-term therapyJ Allergy Clin Immunol20171401162169.e227826098
   PubMed Web of Science ®Google Scholar
• MenzellaFGaleoneCFormisanoDReal-life efficacy of omalizumab after 9 years of follow-upAllergy Asthma Immunol Res20179436837228497924
   PubMed Web of Science ®Google Scholar
• MenzellaFFacciolongoNPiroRClinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-upTher Adv Respir Dis201262879522323442
   PubMed Web of Science ®Google Scholar
• GenentechA Study of MEMP1972A in Patients with Allergic Asthma Inadequately Controlled on Inhaled Steroids and A Second Controller (COSTA)2012 Available from: https://clinicaltrials.gov/ct2/show/NCT01582503Accessed June 6, 2017 ClinicalTrials.gov Identifier: NCT01582503Accessed June 6, 2017
   Google Scholar
• HarrisJMMaciucaRBradleyMSA randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthmaRespir Res20161712926993628
   PubMed Web of Science ®Google Scholar
• GenentechA Study to Investigate the Safety, Tolerability, and Phar-macokinetics of MEMP1972A in Patients with Allergic Rhinitis2010 Available from: https://clinicaltrials.gov/ct2/show/NCT01160861Accessed June 6, 2017 ClinicalTrials.gov Identifier: NCT01160861Accessed June 6, 2017
   Google Scholar
• GenentechA Study of MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients with Mild Asthma (SOLARIO)2010 Available from: https://clinicaltrials.gov/ct2/show/NCT01196039Accessed June 6, 2017 ClinicalTrials.gov Identifier: NCT01196039Accessed June 6, 2017
   Google Scholar
• GauvreauGMHarrisJMBouletLPTargeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE productionSci Transl Med20146243243ra85
   PubMed Web of Science ®Google Scholar
• ArmJPBottoliISkerjanecAPharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjectsClin Exp Allergy201444111371138525200415
   PubMed Web of Science ®Google Scholar
• Novartis PharmaceuticalsEfficacy and Safety of QGE031 versus Placebo and Omalizumab in Patients Aged 18–75 Years With Asthma2012 Available from: https://clinicaltrials.gov/ct2/show?term=CQGE031B2201Accessed July 31, 2017 NLM Identifier: NCT01716754Accessed July 31, 2017
   Google Scholar
• GauvreauGMArmJPBouletLPEfficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responsesJ Allergy Clin Immunol201613841051105927185571
   PubMed Web of Science ®Google Scholar
• StoneKDPrussinCMetcalfeDDIgE, mast cells, basophils, and eosinophilsJ Allergy Clin Immunol20101252 Suppl 2S73S8020176269
   PubMed Web of Science ®Google Scholar
• TanakaHKomaiMNagaoKRole of interleukin-5 and eosinophils in allergen-induced airway remodeling in miceAm J Respir Cell Mol Biol20043116214975941
   PubMed Web of Science ®Google Scholar
• WardlawAJBrightlingCEGreenRWoltmannGBraddingPPavordIDNew insights into the relationship between airway inflammation and asthmaClin Sci (Lond)2002103220121112149112
   PubMed Web of Science ®Google Scholar
• LegrandFKlionADBiologic therapies targeting eosinophils: current status and future prospectsJ Allergy Clin Immunol Pract20153216717425754717
   PubMed Web of Science ®Google Scholar
• LeckieMJten BrinkeAKhanJEffects of an interleukin-5 blocking monoclonal antibody on eosinophils,airway hyper-responsiveness, and the late asthmatic responseLancet200035692482144214811191542
   PubMed Web of Science ®Google Scholar
• Flood-PagePMenzies-GowAPhippsSAnti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmaticsJ Clin Invest200311271029103614523040
   PubMed Web of Science ®Google Scholar
• OrtegaHGLiuMCPavordIDMepolizumab treatment in patients with severe eosinophilic asthmaN Engl J Med2014371131198120725199059
   PubMed Web of Science ®Google Scholar
• PavordIDKornSHowarthPMepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo- controlled trialLancet2012380984265165922901886
   PubMed Web of Science ®Google Scholar
• BelEHWenzelSEThompsonPJOral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthmaN Engl J Med2014371131189119725199060
   PubMed Web of Science ®Google Scholar
• ChuppGLBradfordESAlbersFCEfficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trialLancet Respir Med20175539040028395936
   PubMed Web of Science ®Google Scholar
• Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAn-nouncements/ucm471031.htmAccessed May 27, 2017
   Google Scholar
• Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003860/human_med_001933.jsp&mid=WC0b01ac058001d124Accessed May 27, 2017
   Google Scholar
• CastroMMathurSHargreaveFReslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled studyAm J Respir Crit Care Med2011184101125113221852542
   PubMed Web of Science ®Google Scholar
• Available from: https://www.fda.gov/NewsEvents/Newsroom/Pres-sAnnouncements/ucm491980.htmAccessed May 28, 2017
   Google Scholar
• KolbeckRKozhichAKoikeMMEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity functionJ Allergy Clin Immunol201012561344135320513525
   PubMed Web of Science ®Google Scholar
• MenzellaFLusuardiMGaleoneCFacciolongoNZucchiLThe clinical profile of benralizumab in the management of severe eosinophilic asthmaTher Adv Respir Dis201610653454827612492
   PubMed Web of Science ®Google Scholar
• LavioletteMGossageDLGauvreauGEffects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophiliaJ Allergy Clin Immunol201313251086109623866823
   PubMed Web of Science ®Google Scholar
• GhaziATrikhaACalhounWJBenralizumab – a humanized mAb to IL-5Ralpha with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthmaExpert Opin Biol Ther201212111311822136436
   PubMed Web of Science ®Google Scholar
• CastroMWenzelSEBleeckerERBenralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging studyLancet Respir Med201421187989025306557
   PubMed Web of Science ®Google Scholar
• FitzGeraldJMBleeckerERNairPBenralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialLancet2016388100562128214127609406
   PubMed Web of Science ®Google Scholar
• BleeckerERFitzGeraldJMChanezPEfficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialLancet2016388100562115212727609408
   PubMed Web of Science ®Google Scholar
• NairPWenzelSRabeKFOral glucocorticoid-sparing effect of benralizumab in severe asthmaN Engl J Med2017 Epub ahead of print
   Web of Science ®Google Scholar
• NowakRMParkerJMSilvermanRAA randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthmaAm J Emerg Med2015331142025445859
   PubMed Web of Science ®Google Scholar
• AgrawalS1TownleyRGRole of periostin, FENO, IL-13, lebrikzumab, other IL-13 antagonist and dual IL-4/IL-13 antagonist in asthmaExpert Opin Biol Ther201414216568124283478
   PubMed Web of Science ®Google Scholar
• GandhiNAPirozziGGrahamNMHCommonality of the IL-4/IL-13 pathway in atopic diseasesExpert Rev Clin Immunol201713542543728277826
   PubMed Web of Science ®Google Scholar
• VatrellaAFabozziICalabreseCDupilumab: a novel treatment for asthmaJ Asthma Allergy2014712313025214796
   PubMedGoogle Scholar
• WenzelSFordLPearlmanDDupilumab in persistent asthma with elevated eosinophil levelsN Engl J Med2013368262455246623688323
   PubMed Web of Science ®Google Scholar
• WenzelSCastroMCorrenJDupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trialLancet201638810039314427130691
   PubMed Web of Science ®Google Scholar
• MaselliDJKeytHRogersLProfile of lebrikizumab and its potential in the treatment of asthmaJ Asthma Allergy20158879226309415
   PubMed Web of Science ®Google Scholar
• CorrenJLemanskeRFHananiaNALebrikizumab treatment in adults with asthmaN Engl J Med2011365121088109821812663
   PubMed Web of Science ®Google Scholar
• HananiaNANoonanMCorrenJLebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studiesThorax201570874875626001563
   PubMed Web of Science ®Google Scholar
• HananiaNAKorenblatPChapmanKREfficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trialsLancet Respir Med201641078179627616196
   PubMed Web of Science ®Google Scholar
• PiperEBrightlingCNivenRA phase II placebo-controlled study of tralokinumab in moderate-to-severe asthmaEur Respir J201341233033822743678
   PubMed Web of Science ®Google Scholar
• BrightlingCEChanezPLeighREfficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trialLancet Respir Med20153969270126231288
   PubMed Web of Science ®Google Scholar
• ArimaMFukudaTProstaglandin D2 and T(H)2 inflammation in the pathogenesis of bronchial asthmaKorean J Intern Med201126181821437156
   PubMedGoogle Scholar
• ChevalierE1StockJFisherTCutting edge: chemoattractant receptor-homologous molecule expressed on Th2 cells plays a restricting role on IL-5 production and eosinophil recruitmentJ Immunol200517542056206016081770
   PubMed Web of Science ®Google Scholar
• ErpenbeckVJVetsEGheyleLPharmacokinetics, safety, and tolerability of fevipiprant (QAW039), a novel CRTh2 receptor antagonist: results from 2 randomized, phase 1, placebo-controlled studies in healthy volunteersClin Pharmacol Drug Dev20165430631327310331
   PubMed Web of Science ®Google Scholar
• ErpenbeckVJPopovTAMillerDThe oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthmaPulm Pharmacol Ther201639546327354118
   PubMed Web of Science ®Google Scholar
• GonemSBerairRSingapuriAFevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trialLancet Respir Med20164969970727503237
   PubMed Web of Science ®Google Scholar
• Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf8/P080032b.pdfAccessed May 30, 2017
   Google Scholar
• CoxGThomsonNCRubinASAIR Trial Study GroupAsthma control during the year after bronchial thermoplastyN Engl J Med2007356131327133717392302
   PubMed Web of Science ®Google Scholar
• PavordIDCoxGThomsonNCRISA Trial Study GroupSafety and efficacy of bronchial thermoplasty in symptomatic, severe asthmaAm J Respir Crit Care Med2007176121185119117901415
   PubMed Web of Science ®Google Scholar
• CastroMRubinASLavioletteMAIR2 Trial Study GroupEffectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trialAm J Respir Crit Care Med2010181211612419815809
   PubMed Web of Science ®Google Scholar
• TrivediAPavordIDCastroMBronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthmaLancet Respir Med20164758559227230825
   PubMed Web of Science ®Google Scholar
• MenzellaFZucchiLPiroRA budget impact analysis of bronchial thermoplasty for severe asthma in clinical practiceAdv Ther201431775176125009004
   PubMed Web of Science ®Google Scholar
• ZeinJGMenegayMCSingerMECost effectiveness of bronchial thermoplasty in patients with severe uncontrolled asthmaJ Asthma201653219420026377375
   PubMed Web of Science ®Google Scholar
• PretolaniMDombretMCThabutGReduction of airway smooth muscle mass by bronchial thermoplasty in patients with severe asthmaAm J Respir Crit Care Med2014190121452145425496106
   PubMed Web of Science ®Google Scholar
• DennerDRDoeingDCHogarthDKDuganKNaureckasETWhiteSRAirway inflammation after bronchial thermoplasty for severe asthmaAnn Am Thorac Soc20151291302130926230374
   PubMed Web of Science ®Google Scholar
• RyanDMFowlerSJNivenRMReduction in peripheral blood eosinophil counts after bronchial thermoplastyJ Allergy Clin Immunol2016138130831026953157
   PubMed Web of Science ®Google Scholar
• DebrayMPDombretMCPretolaniMEarly computed tomography modifications following bronchial thermoplasty in patients with severe asthmaEur Respir J2017493160156528298402
   PubMed Web of Science ®Google Scholar
• Arcispedale Santa Maria Nuova-IRCCSBronchial thermoplasty: effect on neuronal and chemosensitive component of the bronchial mucosa (BT-ASMN)2014 Available from: https://clinicaltrials.gov/ct2/show/NCT01839591Accessed April 30, 2017 NLM Identifier: NCT01839591Accessed April 30, 2017
   Google Scholar
• DoeingDCMahajanAKWhiteSRSafety and feasibility of bronchial thermoplasty in asthma patients with very severe fixed airflow obstruction: a case seriesJ Asthma201350221521823252954
   PubMed Web of Science ®Google Scholar
• FajtMLWenzelSEDevelopment of new therapies for severe asthmaAllergy Asthma Immunol Res20179131427826957
   PubMed Web of Science ®Google Scholar
• WenzelSEAsthma phenotypes: the evolution from clinical to molecular approachesNat Med201218571672522561835
   PubMed Web of Science ®Google Scholar
• LommatzschSEMartinRJGoodJTJrImportance of fiberoptic bronchoscopy in identifying asthma phenotypes to direct personalized therapyCurr Opin Pulm Med2013191424823197289
   PubMed Web of Science ®Google Scholar
• DavilaIValeroAEntrenasLMRelationship between serum total IgE and disease severity in patients with allergic asthma in SpainJ Investig Allergol Clin Immunol2015252120127
   PubMed Web of Science ®Google Scholar
• BousquetJRabeKHumbertMPredicting and evaluating response to omalizumab in patients with severe allergic asthmaRespir Med200710171483149217339107
   PubMed Web of Science ®Google Scholar
• WagenerAHde NijsSBLutterRExternal validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthmaThorax201570211512025422384
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKlineOmalizumab to mepolizumab switch study in severe eosinophilic asthma patients2016 Available from: https://clinicaltrials.gov/ct2/show/NCT02654145. NLM Identifier: NCT02654145Accessed may 30, 2017 NLM Identifier: NCT02654145
   Google Scholar
• NachefZKrishnanAMashtareTZhuangTMadorMJOmalizumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: a network meta-analysisJ Asthma2017112
   Web of Science ®Google Scholar
• MagnanABourdinAPrazmaCMTreatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatmentAllergy20167191335134427087007
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKlineCross-sectional study for identification and description of severe asthma patients2014 Available from: https://clinical-trials.gov/ct2/show/NCT02293265. NLM Identifier: NCT02293265Accessed May 30, 2017
   Google Scholar
• ParulekarADAtikMAHananiaNAPeriostin, a novel biomarker of TH2-driven asthmaCurr Opin Pulm Med2014201606524247042
   PubMed Web of Science ®Google Scholar
• WesterhofGAKorevaarDAAmelinkMBiomarkers to identify sputum eosinophilia in different adult asthma phenotypesEur Respir J201546368869626113672
   PubMed Web of Science ®Google Scholar
• IzuharaKOhtaSOnoJUsing periostin as a biomarker in the treatment of asthmaAllergy Asthma Immunol Res20168649149827582399
   PubMed Web of Science ®Google Scholar
• BelEHSousaAFlemingLUnbiased biomarkers for the prediction of respiratory disease outcome (U-BIOPRED) consortium, consensus generation. Diagnosis and definition of severe refractory asthma: an international consensus statement from the innovative medicine initiative (IMI)Thorax2011661091091721106547
   PubMed Web of Science ®Google Scholar
• ChungKFWenzelSEBrozeketJLInternational ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEur Respir J201443234337324337046
   PubMed Web of Science ®Google Scholar
• A budget impact analysis of bronchial thermoplasty for severe asthma in clinical practiceAdv Ther201431775176125009004
   PubMed Web of Science ®Google Scholar
• MenzellaFLusuardiMMontanariGGaleoneCFacciolongoNZucchiLClinical usefulness of mepolizumab in severe eosinophilic asthmaTher Clin Risk Manag20161290791627354806
   PubMed Web of Science ®Google Scholar
• Registry of the Ministry of Health nr. 75/2017 January 19 2017, Nucala. (n. 332/2017). (17A01570) (GU nr.49 / 28-02-2017).
   Google Scholar
• WuACPaltielADKuntzKMWeissSTFuhlbriggeALCost-effectiveness of omalizumab in adults with severe asthma:Results from the asthma policy modelJ Allergy Clin Immunol200712051146115217904628
   PubMed Web of Science ®Google Scholar
• MahajanAKHogarthDKPayer coverage for bronchial thermoplasty: shifting the traditional paradigm for refractory asthma therapyChest201314431051105424008956
   PubMed Web of Science ®Google Scholar